The RE-DUAL PCI trial [6] randomly assigned 2725 patients with AF who had undergone PCI, to receive triple therapy with warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin (for one to three months); dual therapy with dabigatran at a dose of 110 mg twice daily plus a P2Y12 inhibitor; or dual therapy with dabigatran at a dose of 150 mg twice daily plus a P2Y12 inhibitor. The gene discussed is P2RY12; the disease is atrial fibrillation.